The expression of CXCR1/2 on neutrophils was lower than that in patients with chronic hepatitis, which is linked to the dysfunction of neutrophils and the severity of the disease.59 Blocking CXCR1/2 reduces the production of inflammatory mediators and hepatocyte necrosis.63 NGAL is regarded as a biomarker of ACLF and correlates with liver failure and systemic inflammation.64 This evidence concerns the gene CXCR1 and chronic hepatitis.